Acute kidney injury (AKI) is commonly and increasingly encountered in patients with critical illness. Fluid therapy is the cornerstone for the prevention and management of critically ill patients with AKI. New data have emerged that have raised concern that specific types of fluid (i.e. hydroxyethylstarch) may either contribute to or exacerbate AKI. Additional data have accumulated to indicate that the unnecessary accumulation of fluid and volume overload can negatively impact clinical outcomes. This finding may be further compounded in patients with oliguric AKI where solute and free water elimination are impaired. Diuretic therapy in AKI remains controversial. However, diuretic use is common, despite a paucity of evidence to show improved clinical outcomes. There are few therapeutic interventions proven to impact the clinical course and outcome of critically ill patients with established AKI. Current management strategies center largely on supportive care, with rapid resuscitation, removal of the stimulus contributing to AKI, judicious avoidance of complications, and allowing time for recovery. In this review, we explore recent insights on intravenous fluid therapy, volume overload, and diuretic therapy in the context of the critically ill patients with AKI.

Keywords:
Acute kidney injury, Acute renal failure, Volume overload, Hydroxyethylstarch, Loop diuretic, Furosemide, Oliguria, Fluid therapy, Resuscitation
1.
Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.
2.
Bagshaw SM, George C, Dinu I, Bellomo R: A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008;23:1203–1210.
3.
Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35:1837–1843.
4.
Guerin C, Girard R, Selli JM, Perdrix JP, Ayzac L: Initial versus delayed acute renal failure in the intensive care unit: a multicenter prospective epidemiological study. Rhone-Alpes Area Study Group on Acute Renal Failure. Am J Respir Crit Care Med 2000;161:872–879.
5.
Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, Godinez-Luna T, Svenson LW, Rosenal T: Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005;9:R700–R709.
6.
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813–818.
7.
Bagshaw SM, George C, Bellomo R: Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11:R68.
8.
Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM: Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006;17:1143–1150.
9.
Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ: Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006;17:1135–1142.
10.
Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM: Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004;66:1613–1621.
11.
Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml W: Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051–2058.
12.
Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH: Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 2002;40:275–279.
13.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125–139.
14.
Sakr Y, Vincent JL, Reinhart K, Groeneveld J, Michalopoulos A, Sprung CL, Artigas A, Ranieri VM: High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005;128:3098–3108.
15.
Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564–2575.
16.
Van Biesen W, Yegenaga I, Vanholder R, Verbeke F, Hoste E, Colardyn F, Lameire N: Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. J Nephrol 2005;18:54–60.
17.
Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R: Diuretics in the management of acute kidney injury: a multinational survey. Contrib Nephrol 2007;156:236–249.
18.
Abel RM, Beck CH Jr, Abbott WM, Ryan JA Jr, Barnett GO, Fischer JE: Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose: results of a prospective, double-blind study. N Engl J Med 1973;288:695–699.
19.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000;356:26–30.
20.
Schiffl H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305–310.
21.
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.
22.
Venkataraman R, Kellum JA: Prevention of acute renal failure. Chest 2007;131:300–308.
23.
Bellomo R: Fluid resuscitation: colloids vs. crystalloids. Blood Purif 2002;20:239–242.
24.
Vincent JL: Fluid resuscitation: colloids vs. crystalloids. Acta Clin Belg Suppl 2007:408–411.
25.
Vincent JL: The pros and cons of hydroxyethyl starch solutions. Anesth Analg 2007;104:484–486.
26.
McIntyre LA, Fergusson D, Cook DJ, Nair RC, Bell D, Dhingra V, Hutton B, Magder S, Hebert PC: Resuscitating patients with early severe sepsis: a Canadian multicentre observational study. Can J Anaesth 2007;54:790–798.
27.
McIntyre LA, Hebert PC, Fergusson D, Cook DJ, Aziz A: A survey of Canadian intensivists’ resuscitation practices in early septic shock. Crit Care 2007;11:R74.
28.
Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247–2256.
29.
Perel P, Roberts I: Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2007:CD000567.
30.
Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P: Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620–1622.
31.
Cittanova ML, Mavre J, Riou B, Coriat P: Long-term follow-up of transplanted kidneys according to plasma volume expander of kidney donors. Intens Care Med 2001;27:1830.
32.
Dickenamm MJ, Filipovic M, Schneider MC, Brunner FP: Hydroxyethylstarch-associated transient acute renal failure after epidural anaesthesia for labour analgesia and Caesarean section. Nephrol Dial Transplant 1998;13:2706.
33.
Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H: Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248–249.
34.
Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911–916.
35.
Barron ME, Wilkes MM, Navickis RJ: A systematic review of the comparative safety of colloids. Arch Surg 2004;139:552–563.
36.
Sakr Y, Payen D, Reinhart K, Sipmann FS, Zavala E, Bewley J, Marx G, Vincent JL: Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007;98:216–224.
37.
Kellum JA, Cerda J, Kaplan LJ, Nadim MK, Palevsky PM: Fluids for prevention and management of acute kidney injury. Int J Artif Organs 2008;31:96–110.
38.
Gan TJ, Bennett-Guerrero E, Phillips-Bute B, Wakeling H, Moskowitz DM, Olufolabi Y, Konstadt SN, Bradford C, Glass PS, Machin SJ, Mythen MG: Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group. Anesth Analg 1999;88:992–998.
39.
Wiesen P, Canivet JL, Ledoux D, Roediger L, Damas P: Effect of hydroxyethylstarch on renal function in cardiac surgery: a large scale retrospective study. Acta Anaesthesiol Belg 2005;56:257–263.
40.
Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C: Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth 2008;100:504–508.
41.
Pinsky MR, Brophy P, Padilla J, Paganini E, Pannu N: Fluid and volume monitoring. Int J Artif Organs 2008;31:111–126.
42.
Lin SM, Huang CD, Lin HC, Liu CY, Wang CH, Kuo HP: A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 2006;26:551–557.
43.
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.
44.
Michard F, Teboul JL: Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest 2002;121:2000–2008.
45.
Schuller D, Mitchell JP, Calandrino FS, Schuster DP: Fluid balance during pulmonary edema: is fluid gain a marker or a cause of poor outcome? Chest 1991;100:1068–1075.
46.
Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML, Rogers K, Reid C, Tanner AJ, Easley KA: Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004;32:1771–1776.
47.
Gillespie RS, Seidel K, Symons JM: Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. Pediatr Nephrol 2004;19:1394–1399.
48.
Goldstein SL, Currier H, Graf C, Cosio CC, Brewer ED, Sachdeva R: Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 2001;107:1309–1312.
49.
Goldstein SL, Somers MJ, Baum MA, Symons JM, Brophy PD, Blowey D, Bunchman TE, Baker C, Mottes T, McAfee N, Barnett J, Morrison G, Rogers K, Fortenberry JD: Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005;67:653–658.
50.
Simmons RS, Berdine GG, Seidenfeld JJ, Prihoda TJ, Harris GD, Smith JD, Gilbert TJ, Mota E, Johanson WG Jr: Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis 1987;135:924–929.
51.
Uchino S, Bellomo R, Morimatsu H, Sugihara M, French C, Stephens D, Wendon J, Honore P, Mulder J, Turner A: Pulmonary artery catheter versus pulse contour analysis: a prospective epidemiological study. Crit Care 2006;10:R174.
52.
Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lanng C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F: Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg 2003;238:641–648.
53.
Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I: Effect of intraoperative fluid management on outcome after intra-abdominal surgery. Anesthesiology 2005;103:25–32.
54.
Liu KD, Matthay MA, Chertow GM: Evolving practices in critical care and potential implications for management of acute kidney injury. Clin J Am Soc Nephrol 2006;1:869–873.
55.
Mehta RL, Pascual MT, Soroko S, Chertow GM, Group PS: Diuretics, mortality, and nonrecovery of renal function in acute renal failure (see comment). JAMA 2002;288:2547–2553.
56.
Uchino S, Doig GS, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Nacedo E, Gibney N, Tolwani A, Ronco C, Kellum JA: Diuretics and mortality in acute renal failure. Crit Care Med 2004;32:1669–1677.
57.
De Torrente A, Miller PD, Cronin RE, Paulsin PE, Erickson AL, Schrier RW: Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure. Am J Physiol 1978;235:F131–F136.
58.
Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S: Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401–412.
59.
Kramer HJ, Schuurmann J, Wassermann C, Dusing R: Prostaglandin-independent protection by furosemide from oliguric ischemic renal failure in conscious rats. Kidney Int 1980;17:455–464.
60.
Aravindan N, Aravindan S, Riedel BJ, Weng HR, Shaw AD: Furosemide prevents apoptosis and associated gene expression in a rat model of surgical ischemic acute renal failure. Ren Fail 2007;29:399–407.
61.
Aravindan N, Shaw A: Effect of furosemide infusion on renal hemodynamics and angiogenesis gene expression in acute renal ischemia/reperfusion. Ren Fail 2006;28:25–35.
62.
Costa MA, Loria A, Elesgaray R, Balaszczuk AM, Arranz C: Role of nitric oxide pathway in hypotensive and renal effects of furosemide during extracellular volume expansion. J Hypertens 2004;22:1561–1569.
63.
Costa MA, Marchetti M, Balaszczuk AM, Arranz CT: Effects of L-arginine and furosemide on blood pressure and renal function in volume-expanded rats. Clin Exp Pharmacol Physiol 2001;28:528–532.
64.
Croce M, Costa Manso E, Gato JJ, Cordoba H, Oehling A: Furosemide inhibits in vitro histamine release induced by antigens and anti-IgE. J Invest Allergol Clin Immunol 1992;2:205–210.
65.
Oppermann M, Hansen PB, Castrop H, Schnermann J: Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am J Physiol Renal Physiol 2007;293:F279–F287.
66.
Pedersen M, Vajda Z, Stodkilde-Jorgensen H, Nielsen S, Frokiaer J: Furosemide increases water content in renal tissue. Am J Physiol Renal Physiol 2007;292:F1645–F1651.
67.
Beroniade V: Furosemide in acute and chronic renal failure. Dialysis Renal Transplant 1969;5:241–245.
68.
Borirakchanyavat V, Vongsthongsri M, Sitprija V: Furosemide and acute renal failure. Postgrad Med J 1978;54:30–32.
69.
Brown CB, Ogg CS, Cameron JS: High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981;15:90–96.
70.
Brown CB, Ogg CS, Cameron JS, Bewick M: High dose frusemide in acute reversible intrinsic renal failure: a preliminary communication. Scot Med J 1974;19(suppl 1):35–39.
71.
Cantarovich F, Fernandez JC, Locatelli A, Perez Loredo J: Frusemide in high doses in the treatment of acute renal failure. Postgrad Med J 1971;47(suppl):13–17.
72.
Cantarovich F, Galli C, Benedetti L, Chena C, Castro L, Correa C, Perez Loredo J, Fernandez JC, Locatelli A, Tizado J: High dose frusemide in established acute renal failure. Br Med J 1973;4:449–450.
73.
Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL: High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004;44:402–409.
74.
Chandra M, Agarwal SS, Mitra MK, Tandon NN, Gupta NN: Some observations in the management of acute renal failure by massive intravenous frusemide therapy. J Assoc Physicians India 1975;23:415–422.
75.
Chandra M, Agarwal SS, Mitra NK, Gupta NN: Massive intravenous frusemide therapy in acute renal failure. J Indian Med Assoc 1975;64:47–48.
76.
Karayannopoulos S: High-dose frusemide in renal failure. Br Med J 1974;ii:278–279.
77.
Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J: Furosemide in acute oliguric renal failure: a controlled trial. Nephron 1976;17:51–58.
78.
Lucas CE, Zito JG, Carter KM, Cortez A, Stebner FC: Questionable value of furosemide in preventing renal failure. Surgery 1977;82:341–320.
79.
Lumlertgul D, Keoplung M, Sitprija V, Moollaor P, Suwangool P: Furosemide and dopamine in malarial acute renal failure. Nephron 1989;52:40–44.
80.
Minuth AN, Terrell JB Jr, Suki WN: Acute renal failure: a study of the course and prognosis of 104 patients and of the role of furosemide. Am J Med Sci 1976;271:317–324.
81.
Seedat YK: High dose frusemide in established acute renal failure. Br Med J 1973;4:784.
82.
Shilliday IR, Quinn KJ, Allison ME: Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. Nephrol Dialy Transplant 1997;12:2592–2596.
83.
Sirivella S, Gielchinsky I, Parsonnet V: Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Ann Thorac Surg 2000;69:501–506.
84.
Vargas Hein O, Staegemann M, Wagner D, von Heymann C, Martin M, Morgera S, Spies C: Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. Renal Fail 2005;27:385–392.
85.
Zito J, Cortez A, Lucas CE, Stebner FC, Rosenberg IK, Jaanimagi JL: Distribution of renal blood flow after furosemide in critically ill patients. Surg Forum 1976;27:27–29.
86.
Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA: Continuous renal replacement therapy: a worldwide practice survey. The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Intens Care Med 2007;33:1563–1570.
87.
Liangos O, Rao M, Balakrishnan VS, Pereira BJ, Jaber BL: Relationship of urine output to dialysis initiation and mortality in acute renal failure. Nephron Clin Pract 2005;99:c56–c60.
88.
Ho KM, Sheridan DJ: Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006;333:420.
89.
Mehta RL, Cantarovich F, Shaw A, Hoste E, Murray P: Pharmacologic approaches for volume excess in acute kidney injury (AKI). Int J Artif Organs 2008;31:127–144.
90.
Sampath S, Moran JL, Graham PL, Rockliff S, Bersten AD, Abrams KR: The efficacy of loop diuretics in acute renal failure: assessment using Bayesian evidence synthesis techniques. Crit Care Med 2007;35:2516–2524.
91.
Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R: Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc 2007;9:68.
92.
Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA: Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care 2008;23:in press.
93.
Gettings LG, Reynolds HN, Scalea T: Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. Intens Care Med 1999;25:805–813.
94.
Liu KD, Himmelfarb J, Paganini EP, Ikizler A, Soroko S, Mehta RL, Chertow GM: Timing of initiation of dialysis in critically ill patients with acute kidney injury. CJASN 2006;1:915–919.
95.
Kellum JA: Diuretics in acute renal failure: protective or deleterious. Blood Purif 1997;15:319–322.
96.
Kellum JA: Use of diuretics in the acute care setting. Kidney Int Suppl 1998;66:S67–S70.
97.
Lameire N, Vanholder R, Van Biesen W: Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002;288:2599–2601.
98.
Noble DW: Acute renal failure and diuretics: propensity, equipoise, and the need for a clinical trial (comment). Crit Care Med 2004;32:1794–1795.
99.
Schetz M: Should we use diuretics in acute renal failure? Best Pract Res Clin Anaesthesiol 2004;18:75–89.
100.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–R212.
101.
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237–244.
102.
Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231–1238.
103.
Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL: Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005;16:3046–3052.
104.
McIntyre LA, Fergusson DA, Cook DJ, Rankin N, Dhingra V, Granton S: Fluid resuscitation in the management of early septic shock (FINESS): a pilot randomized controlled trial (abstract). Am J Respir Crit Care Med 2008;in press.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.